Reaktion #1980266

ord-0d1b4978659b455eb60d177739cdf37e

Reaktionsgleichung

O
H2O
C#CCCCC#C
1,6-Heptadiyne
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
doxorubicin hydrochloride
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
doxorubicin
O
water
O
water
C#CCCCC#C
1,6-Heptadiyne
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O
ascorbic acid

Lösungsmittel

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Vorschrift

100 mg of product 1 are dissolved in 1.1 ml of distilled water; a solution of 140 μl of 1,6-Heptadiyne in 9.86 ml of DMSO are prepared separately, whereas 23.2 mg of doxorubicin hydrochloride are dissolved in 0.5 ml of distilled water. The solution of hyaluronic acid is mixed with that of doxorubicin and with 0.2 ml of that of 1,6-Heptadiyne; 0.1 ml of an aqueous solution obtained with 50 mg of CuSO4.5H2O in 1 ml of H2O and 0.1 ml of an aqueous solution of 20 mg of ascorbic acid are then added. The mixture is stirred vortically for a few minutes. The rapidly formed gel (see FIG. 28) incorporates the doxorubicin hydrochloride inside.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08512752B2uspto-grants-2013_08